北美肺移植治疗市场，按产品（免疫抑制药物、器官保存产品、组织产品等）、适应症（慢性阻塞性肺病、肺纤维化、脓性肺病、肺动脉高压、囊性纤维化、间质性肺纤维化、肺气肿、结节病、原发性肺动脉高压等）、类型（尸体肺移植、活体肺移植）、技术（单肺移植、双肺移植、心肺移植、双肺移植）、患者人口统计（老年人、成人、儿童）、最终用户（医院、移植中心、专科中心等）、国家（美国、加拿大和墨西哥）划分的行业趋势和预测（至 2029 年）
市场分析与洞察：北美肺移植治疗市场
北美肺移植治疗市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场以 5.9% 的复合年增长率增长，预计到 2029 年将达到 1.1214 亿美元。由于污染增加导致手术和疗法的新创新治疗方法的增加以及呼吸道慢性疾病的增加是推动预测期内市场需求的主要驱动力。
用健康肺（通常来自已故捐赠者）替换患病或衰竭肺的外科手术。肺移植适用于尝试过其他药物或治疗但潜在疾病没有得到充分改善或随着时间的推移而恶化的患者。根据患者的医疗状况，肺移植可能涉及更换一个或两个肺。在某些情况下，肺可能与捐赠的心脏一起移植。肺移植可以显著改善患者的健康和生活质量。
肺部不健康或受损会使患者的身体难以获得维持日常身体功能所需的氧气。各种疾病和状况都会损害您的肺部并妨碍其有效运作。
推动肺移植治疗市场增长的主要因素是肺部相关疾病，例如慢性阻塞性肺病（COPD），包括肺气肿、肺部瘢痕（肺纤维化）、肺部高血压（肺动脉高压）和囊性纤维化疾病，以及一些正在进行的旨在增加治疗应用的研究，而阻碍肺移植治疗市场增长的因素是肺移植治疗和程序的高成本以及产品召回。
肺移植治疗市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报；我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
北美肺移植治疗市场范围和市场规模
北美肺移植治疗市场细分为产品、类型、适应症、技术、患者人口统计和最终用户。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品，北美全球肺移植治疗市场细分为免疫抑制药物、组织产品、器官保存产品等。2022 年，由于器官捐赠及其应用的增加导致市场增长，免疫抑制药物领域预计将主导全球肺移植治疗市场。
- 根据类型，北美全球肺移植治疗市场细分为尸体肺移植和活体肺移植。预计 2022 年，尸体肺移植领域将主导全球肺移植治疗领域，免疫系统抑制药物对患者避免肺排斥的有效性。
- 根据适应症，北美全球肺移植治疗市场细分为慢性阻塞性肺病 (COPD)、肺纤维化、脓性肺病、肺动脉高压、囊性纤维化、间质性肺纤维化、肺气肿、原发性肺动脉高压结节病等。由于该地区囊性纤维化患者中脆弱的老年患者群体增加，预计 2022 年囊性纤维化细分市场将主导全球肺移植治疗市场。
- 根据技术，北美全球肺移植治疗市场细分为单肺移植、双肺移植、心肺移植和双肺移植。由于吸烟和其他有害烟草产品激增，预计 2022 年单肺移植 (SLT) 领域将主导全球肺移植治疗市场
- 根据患者人口统计数据，北美全球肺移植治疗市场分为成人、儿童和老年。由于全球人口的增长，预计到 2022 年，成人市场将主导全球肺移植治疗市场。
- 根据最终用户，北美全球肺移植治疗市场分为医院、移植中心、专科中心和其他。到 2022 年，由于拥有高效手术和高技能医生的医院数量增加，预计医院部门将主导全球肺移植治疗市场。
北美肺移植治疗市场国家级分析
对肺移植治疗市场进行分析，并根据产品、类型、适应症、技术、患者人口统计和最终用户提供市场规模信息。
北美肺移植治疗市场报告涵盖的国家包括美国、加拿大和墨西哥。
- 2022 年，由于慢性阻塞性肺病 (COPD) 等肺部相关疾病的增加，预计美国将主导北美肺移植治疗市场。
由于预防慢性病的临床试验和研究开发不断增加，预计美国免疫抑制药物市场将在 2022 年至 2029 年的预测期内以最高增长率增长。加拿大预计也将实现增长，因为每年肺移植手术的增加导致移植药物的批准增加，研发投资不断增加，从而推动了制药创新。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
严重肺部疾病患病率上升推动市场增长
北美肺移植治疗市场还为您提供有关每个国家肺移植行业增长的详细市场分析，包括销售额、肺移植技术进步的影响以及监管环境的变化及其对肺移植治疗市场的支持。数据涵盖 2012 年至 2020 年的历史时期。
竞争格局和肺移植治疗市场份额分析
肺移植治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上数据点仅与公司对北美肺移植治疗的关注有关。
北美肺移植治疗市场的一些主要制造商包括安斯泰来制药公司、诺华公司、辉瑞公司、罗氏公司、诺华公司、Accord UK Ltd、Panacea Biotech Ltd、Dr、Franz Kohler Chemie GMBH、Dr. Reddy's laboratories Ltd、Detraxi Inc、Hikma Pharmaceuticals PLC、Apotex Inc.、Intas Pharmaceuticals Ltd.、Viatris Inc.、Bridge to Life Ltd.、Transmedics Inc.、Paragonix Technologies Inc.、Xvivo、OSE Immunotherapeutics、BioLife Solutions 和 21st Century Medicine 等。
各种市场参与者提供更好的医疗服务，这也加速了肺移植治疗市场的发展
例如，
- 2021 年 7 月，美国食品药品监督管理局根据一项提供真实世界有效性证据 (RWE) 的非干预性（观察性）研究批准了 Prograf（他克莫司）的新用途。FDA 批准 Prograf 与其他免疫抑制剂药物联合使用，以防止接受肺移植的成人和儿科患者的器官排斥
合作、产品发布、业务扩展、奖励和认可、合资企业和其他市场参与者增强了公司在肺移植治疗市场的地位，这也有利于该组织改善其产品供应。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 CANADA
6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.1 SEPTIC LUNG DISEASE
13.11 OTHERS
14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY
15.1 OVERVIEW
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDY’S LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 INTAS PHARMACEUTICALS LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 NOVARTIS AG
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 PANACEA BIOTEC LTD.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 PARAGONIX TECHNOLOGIES, INC
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.15.3.1 PRODUCT LAUNCH
18.15.3.2 PARTNERSHIP
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 VIATRIS, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 21ST CENTURY MEDICINE
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 17 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 18 U.S. IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 19 U.S. CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 20 U.S. ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 21 U.S. M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 22 U.S. STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 23 U.S. MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 24 U.S. IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.S. IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 U.S. ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 28 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 30 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 31 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 CANADA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 34 CANADA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 35 CANADA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 36 CANADA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 37 CANADA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 38 CANADA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 39 CANADA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 41 CANADA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 43 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 45 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 46 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 48 MEXICO IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 49 MEXICO CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 50 MEXICO ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 51 MEXICO M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 52 MEXICO STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 53 MEXICO MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 54 MEXICO IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 MEXICO IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 56 MEXICO ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 58 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 60 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 61 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
FIGURE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021
FIGURE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021
FIGURE 19 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021
FIGURE 23 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 27 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021
FIGURE 31 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021
FIGURE 35 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)
FIGURE 43 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
